Argenx rises after Q3 earnings beat on strong sales growth By Investing.com
Update: 2025-10-30
Description
Argenx, a Belgian biopharmaceutical company, has reported impressive third-quarter results, with global product net sales surging by 96% year-over-year to $1.13 billion, exceeding expectations. The company's U.S. sales also outperformed estimates. Driven by growth in treatments for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, Argenx posted a profit of $344 million, with a solid 30% profit margin. Despite significant R&D and administrative expenses, the company remains on track with its guidance for the year. With nine-month product sales already at $2.87 billion, Argenx is well ahead of its 2021 sales and poised for a strong 2023. The company's growth is supported by strong major therapy growth, new patient starts, and a robust cash position of over $4 billion. Looking ahead, Argenx has a busy pipeline with five major clinical results expected in 2026 and several milestones planned over the next two years, positioning it as a leader in the biotech sector.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
